CF
TRDA icon

Cantor Fitzgerald’s Entrada Therapeutics TRDA Stock Holding History

Cantor Fitzgerald’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Buy
60,000
+13,000
+28% +$125K ﹤0.01% 291
2026
Q1 		$593K Sell
47,000
-10,000
-18% -$115K 0.01% 207
2025
Q4 		$586K Sell
57,000
-10,334
-15% -$87.1K 0.01% 178
2025
Q3 		$3.91M Buy
+67,334
New +$394K 0.04% 125

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Cantor Fitzgerald's TRDA Position: Q2 2026 in Review

Cantor Fitzgerald increased its Entrada Therapeutics (TRDA) stake by 28% in Q2 2026, buying an estimated $125K and bringing the position to 60,000 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #291.

Cantor Fitzgerald first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.91M in Q3 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Cantor Fitzgerald held 60,000 shares of Entrada Therapeutics worth $442K as of Q2 2026.
  • Cantor Fitzgerald bought 13,000 Entrada Therapeutics shares in Q2 2026, an estimated $125K.
  • Entrada Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q2 2026, its #291 holding.
  • Cantor Fitzgerald first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Cantor Fitzgerald's Entrada Therapeutics position peaked at $3.91M in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.